238 related articles for article (PubMed ID: 28973509)
1. Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy.
Park JS; Lim DH; Ahn YC; Park W; Kim SJ; Kim WS; Kim K
Jpn J Clin Oncol; 2017 Nov; 47(11):995-1001. PubMed ID: 28973509
[TBL] [Abstract][Full Text] [Related]
2. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
[TBL] [Abstract][Full Text] [Related]
7. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
9. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Laack NN; O'Neill BP; Ballman KV; O'Fallon JR; Carrero XW; Kurtin PJ; Scheithauer BW; Brown PD; Habermann TM; Colgan JP; Gilbert MR; Hawkins RB; Morton RF; Windschitl HE; Fitch TR; Pajon ER;
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):476-82. PubMed ID: 20800387
[TBL] [Abstract][Full Text] [Related]
10. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
[TBL] [Abstract][Full Text] [Related]
11. Significance of treatment response when managing patients with primary central nervous system lymphoma.
Chan H; Moraes FY; Berlin A; Crump M; Mason W; Laperriere N; Kuruvilla J; Prica A
Leuk Lymphoma; 2019 Feb; 60(2):349-357. PubMed ID: 29966463
[TBL] [Abstract][Full Text] [Related]
12. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
13. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
14. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
[TBL] [Abstract][Full Text] [Related]
16. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Bessell EM; López-Guillermo A; Villá S; Verger E; Nomdedeu B; Petit J; Byrne P; Montserrat E; Graus F
J Clin Oncol; 2002 Jan; 20(1):231-6. PubMed ID: 11773174
[TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
18. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
19. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]